Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy

Apr 26 2018

• By Emily Hayes

Men and women couple carrying a cardboard box

Related Content

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Nov 14 2017

Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer

Apr 20 2018

Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial

Mar 12 2018

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Apr 17 2018

In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

Apr 18 2018

Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

Apr 06 2018

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Apr 23 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Johnson & Johnson

Pfizer Inc.

Merck KGaA

Additional Topics

ImmunoOncology Sales & Earnings Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window